EP2175844A1 - Substituted fluoroethyl ureas as alpha 2 adrenergic agents - Google Patents

Substituted fluoroethyl ureas as alpha 2 adrenergic agents

Info

Publication number
EP2175844A1
EP2175844A1 EP08771647A EP08771647A EP2175844A1 EP 2175844 A1 EP2175844 A1 EP 2175844A1 EP 08771647 A EP08771647 A EP 08771647A EP 08771647 A EP08771647 A EP 08771647A EP 2175844 A1 EP2175844 A1 EP 2175844A1
Authority
EP
European Patent Office
Prior art keywords
pain
compound
atoms
disease
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08771647A
Other languages
German (de)
French (fr)
Inventor
Wenkui K. Fang
Ken Chow
Evelyn G. Corpuz
Daniel W. Gil
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of EP2175844A1 publication Critical patent/EP2175844A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • n 0 or 1
  • A is cyclohexyl having 0, 1, 2, 3, or 4 substituents wherein the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
  • substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
  • Another embodiment is use of a compound disclosed herein in the manufacture of a medicament for the treatment of pain.
  • the pain is chronic pain. "Chronic pain is pain that persists or recurs for [greater than] 3 months, persists [for greater than] 1 month after resolution of an acute tissue injury, or accompanies a nonhealing lesion.” (Online Merck Manual, Eighteenth Edition.) [7] In another embodiment the pain is neuropathic pain. "Neuropathic pain results from damage to or dysfunction of the peripheral or central nervous system.” (Online Merck Manual, Eighteenth Edition.)
  • the pain is visceral pain.
  • “Visceral pain comes from the abdominal viscera, which are innervated by autonomic nerve fibers and respond mainly to the sensations of distention and muscular contraction.” (Online Merck Manual, Eighteenth Edition.)
  • the pain is allodynia. Allodynia is "pain due to a nonnoxious stimulus.” (Online Merck Manual, Eighteenth Edition.) [10] In another embodiment the pain is associated with muscle spasticity. [11] In another embodiment the pain is associated with diarrhea. [12] For the purposes of this disclosure, “treat,” “treating,” or “treatment” refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
  • the compounds can be used to treat include hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, stroke, drug dependence, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and combinations thereof.
  • reference to a compound should be construed broadly to include pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, and non-covalent complexes of a chemical entity of the depicted structure or chemical name.
  • a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
  • a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
  • a salt is a chemical species having an ionic form of the compound, such as a conjugate acid or base, associated with a corresponding amount of counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
  • a prodrug is a compound which is converted to a therapeutically active compound after administration to an animal or human. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group.
  • Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496- 557, provides further detail on the subject.
  • Tautomers are isomers that are in rapid equilibrium with one another. For example, they may include a transfer of a proton, hydrogen atom, or hydride ion.
  • the structures herein are intended to include, but are not limited to, the tautomeric forms shown below.
  • Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
  • alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
  • Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
  • n is 0 or 1
  • the following compounds are possible.
  • the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I.
  • substituents include, but are not limited to:
  • Hydrocarbyl meaning a moiety consisting of carbon and hydrogen only, including, but not limited to:
  • alkyl meaning hydrocarbyl having no double or triple bonds, including, but not limited to:
  • linear alkyl e.g. methyl, ethyl, w-propyl, w-butyl, w-pentyl, w-hexyl, etc.
  • branched alkyl e.g. ⁇ o-propyl, ?-butyl and other branched butyl isomers, branched pentyl isomers, etc.
  • cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • combinations of linear, branched, and/or cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • alkenyl e.g. hydrocarbyl having 1 or more double bonds, including linear, branched, or cycloalkenyl
  • alkynyl e.g. hydrocarbyl having 1 or more triple bonds, including linear, branched, or cycloalkenyl
  • alkyl-CN such as -CH 2 -CN, -(CH 2 ) 2 -CN; -(CH 2 ) 3 -CN, and the like; [33] hydroxyalkyl, i.e. alkyl-OH, such as hydroxymethyl, hydroxyethyl, and the like; [34] ether substituents, including -O-alkyl, alkyl-O-alkyl, and the like; [35] thioether substituents, including -S-alkyl, alkyl-S-alkyl, and the like; [36] amine substituents, including -NH 2 , -NH-alkyl j -N-alky ⁇ alkyl 2 (i.e., alkyl 1 and alkyl 2 are the same or different, and both are attached to N), alkyl-NH 2 , alkyl-NH-alkyl, alkyl-N-alkyl 1 alkyl 2 , and the like;
  • aminoalkyl meaning alkyl-amine, such as aminomethyl (-CH 2 -amine), aminoethyl, and the like; [38] ester substituents, including -CO 2 -alkyl, -CO 2 _phenyl, etc.; [39] other carbonyl substituents, including aldehydes; ketones, such as acyl (i.e. o
  • hydrocarbyi an( j ⁇ jjj ⁇ g. m particular, acetyl, propionyl, and benzoyl substituents are contemplated;
  • fluorocarbons or hydroflourocarbons such as -CF 3 , _CH 2 CF 3 , etc.; and [42] -CN;
  • a substituent may be -F, -Cl, -Br, or -I.
  • alkyl having from 1 to 8 carbon atoms is contemplated as a substituent.
  • alkyl having from 1 to 4 carbon atoms is contemplated; [47] Substituents must be sufficiently stable to be stored in a bottle at room temperature under a normal atmosphere for at least 12 hours, or stable enough to be useful for any purpose disclosed herein.
  • a substituent is a salt, for example of a carboxylic acid or an amine
  • the counter-ion of said salt i.e. the ion that is not covalently bonded to the remainder of the molecule is not counted for the purposes of determining the number of atoms in a substituent.
  • the salt -CO 2 Na + is a stable substituent consisting of 1 carbon atom and 2 oxygen atoms, i.e. sodium is not counted.
  • the salt -NH(Me) 2 + Cl " is a stable substituent consisting of 1 nitrogen atom, 2 carbon atoms, and 7 hydrogen atoms, i.e. chlorine is not counted.
  • the substituents are independently C 1 - 4 alkyl, C 1 -3 alkoxy, F, Cl, Br, I, or NH 2 .
  • Ci_6 alkyl means alkyl having from 1 to 6 carbon atoms
  • Ci_6 hydrocarbyl means hydrocarbyl having from 1 to 6 carbon atoms.
  • Another embodiment is a compound having the formula
  • R 1 is alkyl having from 1 to 6 carbon atoms.
  • R 1 is w-propyl, i.e. -CH 2 CH 2 CH 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Treating pain in mammals with a compound having the formula (I) is disclosed herein.

Description

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC
AGENTS
by Inventors
Wenkui K. Fang, Ken Chow, Evelyn G. Corpuz, Daniel W. Gil, and Michael E. Garst
CROSS-REFERENCE
[1] This application claims the benefit of U.S. Application serial number 60/948,389, filed July 6, 2007, which is hereby incorporated by reference in its entirety.
DESCRIPTION OF THE INVENTION
[2] Compounds are disclosed herein having the formula
wherein n is 0 or 1; and
A is cyclohexyl having 0, 1, 2, 3, or 4 substituents wherein the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I. [3] These compounds are useful for treating pain in a mammal. [4] One embodiment is a method of treating pain comprising administering a compound disclosed herein.
[5] Another embodiment is use of a compound disclosed herein in the manufacture of a medicament for the treatment of pain.
[6] In one embodiment the pain is chronic pain. "Chronic pain is pain that persists or recurs for [greater than] 3 months, persists [for greater than] 1 month after resolution of an acute tissue injury, or accompanies a nonhealing lesion." (Online Merck Manual, Eighteenth Edition.) [7] In another embodiment the pain is neuropathic pain. "Neuropathic pain results from damage to or dysfunction of the peripheral or central nervous system." (Online Merck Manual, Eighteenth Edition.)
[8] In another embodiment the pain is visceral pain. "Visceral pain comes from the abdominal viscera, which are innervated by autonomic nerve fibers and respond mainly to the sensations of distention and muscular contraction." (Online Merck Manual, Eighteenth Edition.)
[9] In another embodiment the pain is allodynia. Allodynia is "pain due to a nonnoxious stimulus." (Online Merck Manual, Eighteenth Edition.) [10] In another embodiment the pain is associated with muscle spasticity. [11] In another embodiment the pain is associated with diarrhea. [12] For the purposes of this disclosure, "treat," "treating," or "treatment" refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition. Other indications that the compounds can be used to treat include hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, stroke, drug dependence, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and combinations thereof. [13] Unless otherwise indicated, reference to a compound should be construed broadly to include pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, and non-covalent complexes of a chemical entity of the depicted structure or chemical name.
[14] A pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt. A salt is a chemical species having an ionic form of the compound, such as a conjugate acid or base, associated with a corresponding amount of counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions). [15] A prodrug is a compound which is converted to a therapeutically active compound after administration to an animal or human. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems," which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496- 557, provides further detail on the subject.
[16] Tautomers are isomers that are in rapid equilibrium with one another. For example, they may include a transfer of a proton, hydrogen atom, or hydride ion. For example, the structures herein are intended to include, but are not limited to, the tautomeric forms shown below.
[17] Unless stereochemistry is explicitly depicted, a structure is intended to include any possible stereoisomer, both pure or in any possible isomeric mixture.
[18] Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein. For example, alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
[19] Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
[20] Because n is 0 or 1, the following compounds are possible.
[21] The substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 17 hydrogen atoms; F; Cl; Br; or I. [22] Subject to the constraints described herein (e.g. limits on the number of atoms for a substituent), examples of substituents include, but are not limited to: [23] Hydrocarbyl, meaning a moiety consisting of carbon and hydrogen only, including, but not limited to:
[24] alkyl, meaning hydrocarbyl having no double or triple bonds, including, but not limited to:
[25] linear alkyl, e.g. methyl, ethyl, w-propyl, w-butyl, w-pentyl, w-hexyl, etc., [26] branched alkyl, e.g. ώo-propyl, ?-butyl and other branched butyl isomers, branched pentyl isomers, etc.,
[27] cycloalkyl, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc., [28] combinations of linear, branched, and/or cycloalkyl;
[29] alkenyl, e.g. hydrocarbyl having 1 or more double bonds, including linear, branched, or cycloalkenyl
[30] alkynyl, e.g. hydrocarbyl having 1 or more triple bonds, including linear, branched, or cycloalkenyl;
[31] combinations of alkyl, alkenyl, and/or akynyl
[32] alkyl-CN, such as -CH2-CN, -(CH2)2-CN; -(CH2)3-CN, and the like; [33] hydroxyalkyl, i.e. alkyl-OH, such as hydroxymethyl, hydroxyethyl, and the like; [34] ether substituents, including -O-alkyl, alkyl-O-alkyl, and the like; [35] thioether substituents, including -S-alkyl, alkyl-S-alkyl, and the like; [36] amine substituents, including -NH2, -NH-alkylj-N-alky^alkyl2 (i.e., alkyl1 and alkyl2 are the same or different, and both are attached to N), alkyl-NH2, alkyl-NH-alkyl, alkyl-N-alkyl1 alkyl2, and the like;
[37] aminoalkyl, meaning alkyl-amine, such as aminomethyl (-CH2-amine), aminoethyl, and the like; [38] ester substituents, including -CO2-alkyl, -CO2_phenyl, etc.; [39] other carbonyl substituents, including aldehydes; ketones, such as acyl (i.e. o
\ hydrocarbyi^ an(j ^ jjj^g. m particular, acetyl, propionyl, and benzoyl substituents are contemplated;
[40] phenyl or substituted phenyl;
[41] fluorocarbons or hydroflourocarbons such as -CF3, _CH2CF3, etc.; and [42] -CN;
[43] combinations of the above are also possible, subject to the constraints defined; [44] Alternatively, a substituent may be -F, -Cl, -Br, or -I. [45] In particular, alkyl having from 1 to 8 carbon atoms is contemplated as a substituent.
[46] Alternatively, alkyl having from 1 to 4 carbon atoms is contemplated; [47] Substituents must be sufficiently stable to be stored in a bottle at room temperature under a normal atmosphere for at least 12 hours, or stable enough to be useful for any purpose disclosed herein.
[48] If a substituent is a salt, for example of a carboxylic acid or an amine, the counter-ion of said salt, i.e. the ion that is not covalently bonded to the remainder of the molecule is not counted for the purposes of determining the number of atoms in a substituent. Thus, for example, the salt -CO2 Na+ is a stable substituent consisting of 1 carbon atom and 2 oxygen atoms, i.e. sodium is not counted. In another example, the salt -NH(Me)2 +Cl" is a stable substituent consisting of 1 nitrogen atom, 2 carbon atoms, and 7 hydrogen atoms, i.e. chlorine is not counted.
[49] In one embodiment the substituents are independently C1-4 alkyl, C1-3 alkoxy, F, Cl, Br, I, or NH2.
[50] Use of the notation "Cx-y" means the moiety has from x to y carbon atoms. For example, Ci_6 alkyl means alkyl having from 1 to 6 carbon atoms, or Ci_6 hydrocarbyl means hydrocarbyl having from 1 to 6 carbon atoms. [51] Another embodiment is a compound having the formula
[52] wherein R1 is alkyl having from 1 to 6 carbon atoms. [53] In another embodiment, R1 is w-propyl, i.e. -CH2CH2CH3.
Biological Data
[54] United States Provisional Patent Application Serial No. 60/911442, filed April 12, 2007, describes the procedure used to obtain the data in the table below. That procedure is incorporated by reference herein.
[55] Synthesis of l-(2-fluoro-ethyl)-3-(2/?-propyl-l/?-cyclohexyl)-urea:
[56] l-(2-Fluoro-ethyl)-3-(2R-propyl-lR-cyclohexyl)-urea: The title compound was obtained from 2R -propyl- lR-cyclohexylamine (1.40 g, 10.00 mmol), diimidazole carbonyl (1.70 g, 10.48 mmol), fluoroethyl amine hydrochloride (1.00 g, 90% purity, 9.05 mmol) and diisopropylethyl amine (3.60 mL, 20.67 mmol) according to the protocols as outlined in general procedure A, incorporated by reference, of US 60/911442, filed April 12, 2007. Spectroscopic data: 1H NMR (300 MHz, DMSCM6) δ ppm θ.76 - 0.88 (m, 2 H) 1.21 (s, 2 H) 1.36 (s, 2 H) 3.57 (s, 2 H) 4.51 (s, 4 H) 4.66 (s, 2 H) 7.19 (s, 4 H) 7.29 (s, 2 H) 7.43 (s, 4 H) 8.75 (s, 2 H).
[57] Methods of formulating these compounds are well known in the art. For example, United States Patent No. 7,141,597 (especially column 10, line 27 to column 14, line 47) contains information that may be used for general guidance. Similar relevant information is also available in numerous other sources. The biological activity of the compounds disclosed herein (e.g. Table 1) may be used for additional general guidance on dosage, depending on the particular use of a compound.
[58] The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the claims.

Claims

CLAIMSWhat is claimed is;
1. A method of treating pain comprising administering a compound to a mammal in need thereof, said compound having the formula
wherein n is 0 or 1 ; and
A is cyclohexyl having 0, 1, 2, 3, or 4 substituents wherein the substituents each independently consist of: a moiety consisting of from 0 to
8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 22 hydrogen atoms; F; Cl; Br; or I.
2. The method of claim 1 wherein the pain is chronic pain.
3. The method of claim 1 wherein the pain is neuropathic pain.
4. The method of claim 1 wherein the pain is visceral pain.
5. The method of claim 1 wherein the pain is allodynia.
6. The method of claim 1 wherein the pain is associated with muscle spasticity.
7. The method of claim 1 wherein the pain is associated with diarrhea.
8. A compound having the formula
wherein R1 is alkyl having from 1 to 6 carbon atoms.
9. The compound of claim 8 wherein R1 is w-propyl.
10. The compound of claim 8 wherein the compound may be used to treat hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, stroke, drug dependence, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and combinations thereof.
11. A compound having the formula
wherein n is 0 or 1; and
A is cyclohexyl having 0, 1, 2, 3, or 4 substituents wherein the substituents each independently consist of: a moiety consisting of from 0 to 8 carbon atoms, 0 or 1 nitrogen atoms, 0 or 1 oxygen atoms, 0 or 1 sulfur atoms, 0 to 3 fluorine atoms, and from 0 to 22 hydrogen atoms; F; Cl; Br; or I.
12. The compound of claim 11 wherein the compound may be used to treat hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, stroke, drug dependence, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and combinations thereof.
EP08771647A 2007-07-06 2008-06-20 Substituted fluoroethyl ureas as alpha 2 adrenergic agents Withdrawn EP2175844A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94838907P 2007-07-06 2007-07-06
PCT/US2008/067748 WO2009009278A1 (en) 2007-07-06 2008-06-20 Substituted fluoroethyl ureas as alpha 2 adrenergic agents

Publications (1)

Publication Number Publication Date
EP2175844A1 true EP2175844A1 (en) 2010-04-21

Family

ID=39791193

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08771647A Withdrawn EP2175844A1 (en) 2007-07-06 2008-06-20 Substituted fluoroethyl ureas as alpha 2 adrenergic agents

Country Status (2)

Country Link
EP (1) EP2175844A1 (en)
WO (1) WO2009009278A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6178724A (en) * 1984-09-25 1986-04-22 Tetsuo Suami antitumor agent
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7709507B2 (en) * 2006-05-17 2010-05-04 Allergan, Inc. Therapeutic fluoroethyl ureas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009009278A1 *

Also Published As

Publication number Publication date
WO2009009278A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
RU2213743C2 (en) Derivative of thienylazolylalkoxyethaneamine, method for its preparing (variants), pharmaceutical composition, intermediate compound and method for its preparing (variants)
US12454516B2 (en) Nitric oxide releasing prodrugs of MDA and MDMA
US12012381B2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
RU2006113700A (en) AMINO SUBSTITUTED ETHYLAMITO-AGONISTS OF BETA2-ADRENERGIC RECEPTORS
CA3215210A1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
WO2007017092A1 (en) Substituted 4-benzyloxy-benzoic acid amide derivatives
EP2491017B1 (en) Alpha adrenergic receptor modulators
US8080570B2 (en) α2B and α2C agonists
WO2007080109A1 (en) Substituded benzyloxy-phenylmethylurea derivatives
WO2017022733A1 (en) Piperazine derivative
US11590089B2 (en) Beta-2 selective adrenergic receptor agonists
DE3687035T2 (en) 3-AMINOPROPYLOXYPHENYLAB COLLECTIBLES, PRODUCTION AND MEDICINAL PRODUCTS THAT CONTAIN.
EP2175844A1 (en) Substituted fluoroethyl ureas as alpha 2 adrenergic agents
US20110028559A1 (en) Substituted fluoroethyl ureas as alpha 2 adrenergic agents
CN106795100A (en) Compound, pharmaceutical composition and its purposes in nerve degenerative diseases are treated
MX2011001846A (en) Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors.
EP2188261A1 (en) Therapeutic compounds
WO2015046405A1 (en) Analgesic
EP1497256B1 (en) Substituted 1,5-diaminopentan-3-ol compounds
MX2011001847A (en) Piperidylpropionamide derivatives useful for the treatment of cns disorders including depression and panic disorder.
WO2009023758A1 (en) Heterocyclyl substituted fused carbocyles useful in the treatment of conditions such as glaucoma and pain
KR20250020444A (en) Azetidine compounds, pharmaceutical compositions thereof, processes for their preparation and their use in the treatment of diseases of the central nervous system
US20100197729A1 (en) Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
JPWO1999043656A1 (en) Propylamine derivatives and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120102